Article Text

Download PDFPDF
Clinical characteristics
F04 Quality of life in Huntington's disease: a comparative study investigating the impact on spouses of those with premanifest and early disease
  1. J E Read1,
  2. T P A2,
  3. D R Langbehn2,
  4. G Owen1,
  5. A Dürr3,
  6. B R Leavitt4,
  7. R A C Roos5,
  8. J C Stout6,
  9. S J Tabrizi1,
  10. D Craufurd7,
  11. TRACK-HD investigators
  1. 1Institute of Neurology, University College London, London, UK
  2. 2Departments of Psychiatry and Biostatistics (secondary), University of Iowa, USA
  3. 3Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris France
  4. 4Department of Medical Genetics, University of British Columbia, Canada
  5. 5Department of Neurology, Leiden University Medical Centre, The Netherlands
  6. 6School of Psychology, Psychiatry, and Psychological Medicine, Monash University, Victoria, Australia
  7. 7University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, UK


Background Huntington's disease (HD) is a progressive, inherited neurodegenerative condition, with onset usually in mid-life, affecting motor, cognitive and neuropsychiatric functions. Not surprisingly, studies have suggested that HD has a detrimental effect on the quality of life (QoL) of individuals with the HD gene expansion and also by association their families. The present literature exploring the impact for spouses predominantly investigates the later stages of HD. This study, however, uses clearly defined groups of both premanifest and early-stage symptomatic gene-carriers and their spouse/partners.

Methods/techniques Self-report measures of quality of life and neuropsychiatric domains (SF-36; Quality of Life Index; Frontal Systems Behaviour Inventory (FrSBe)), clinical rating of motor function (UHDRS motor), Cognitive measures (Emotion Recognition, Trails-B) and the Short version of Problem Behaviours Assessment for HD (PBA-s) were completed by 86 participants from the TRACK-HD study. This included 23 pre-manifest gene carriers, 20 early, clinical stage 1 and 2, HD patients and 43 gene-negative spouse controls. Between-group differences and relationships between neuropsychiatric and cognitive data from the premanifest and symptomatic participants and QoL for their spouses were examined.

Results/outcomes Largest between-group differences were evident between spouses and their partners with early stage disease; and different QoL domains were impacted in the different participant groups. The data presented shows the QoL domains affected in each group; and the impact of specific neuropsychiatric, cognitive and motor symptoms on spouse partners. Identification of the specific domains impacted in spouse/partners at an early stage of disease is crucial for establishing appropriate and long-term support.

  • Quality of life
  • spouses/partners

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.